ArticleJournal of nanobiotechnology2026
A dual-pronged strategy: multi-bioactive nanoplatform synergizes ROS antidote and iron stabilization to protect against liver ischemia-reperfusion injury.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Liver ischemia-reperfusion injury (LIRI) is a severe and nearly unavoidable complication in hepatectomy and liver transplantation, accompanied by intense oxidative stress and ferroptosis. Traditional clinical therapies often face challenges such as poor bioavailability, short circulation time, and low stability, which restrict their efficacy in regulating complex pathological microenvironments. Here, we developed a biocompatible and multi-bioactive nanoplatform, Se@MelP, comprising a selenium nanoparticle (SeNP) core encapsulated within a melanin-like shell. Specifically, selenium (Se) was incorporated into selenoproteins in the form of selenocysteine to regulate redox reactions, while the melanin-like shell simultaneously scavenged reactive oxygen species (ROS) and chelated Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.